Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

One panelist accused the F.D.A. of withholding data on potential harms. The advisers also are reviewing research on vaccines ...

A federal judge just invoked Star Trek in a $5 billion patent ruling against Moderna. Here is why the mRNA giant is heading ...

Moderna (MRNA) is back in focus after pairing a new rare disease collaboration on mRNA-3927 with Recordati with a leadership ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Moderna (MRNA) reports results for the ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Global mRNA Synthesis and Manufacturing Market OverviewThe global mRNA synthesis and manufacturing market is projected to grow at a compound annual growth rate of approximately 6% during the forecast ...

Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

If you are wondering whether Moderna's share price still reflects its underlying worth, it helps to start with the recent ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.